PATP1280.03 - NeuroReset™

AI-Assisted Technical Review

NeuroReset™ is presented within the BII portfolio as a research-stage, patent-pending investigational platform focused on recovery-related central nervous system biology. The PATP1280.03 technical review examines a multi-site targeted therapeutic conjugate designed for coordinated intracellular release of two pharmacologically complementary ligands, with investigational focus on neuroinflammation, post-dependency cognitive recovery, mood dysregulation, and relapse vulnerability.

This AI-assisted technical review examines the patent family from a scientific and technical perspective, including:

• invention scope

• mechanism logic

• conjugate architecture

• claims structure

• receptor/selectivity data

• biosynthetic manufacturing concepts

• technical strengths and open questions

• Public Summary

PATP1280.03 describes a bifunctional small-molecule drug conjugate that pairs:

• a serotonergic / sigma-1 pharmacophore

• with a CB2-selective cannabinoid pharmacophore

• connected by a hydrolytically or enzymatically cleavable linker intended to release both active species intracellularly after uptake.

• The technical review frames this platform around a dual-mechanism research model in which:

• the serotonergic / sigma-1 arm is intended to support neuritogenesis and BDNF-related biology

• the CB2-selective arm is intended to influence cAMP / PKA-linked inflammatory and recovery-relevant signaling

• the linker strategy is designed to coordinate intracellular release and study pathway interaction in a single investigational construct

• Within the AI-assisted review, key areas of interest include:

• CB2/CB1 selectivity

• 5-HT2A, 5-HT1A, and sigma-1 receptor logic

• multi-site conjugate design

• phosphate-cleavable intracellular release

• research-stage recovery biology applications

• biosynthesis and modular manufacturing concepts

Why This Technical Review Matters

At BII, AI-assisted technical reviews are used to organize complex patent information into a clearer scientific framework.

For PATP1280.03, this review helps clarify:

• how NeuroReset™ is positioned mechanistically

• how the conjugate architecture is described

• how the claims are organized

• what receptor and selectivity data appear in the filing

• what technical questions may still require further validation or expert review

• This page is intended as a public-facing summary only.

• It is not legal advice, not a regulatory conclusion, and not clinical evidence.

• Research-Stage Positioning

NeuroReset™ remains a research-stage, investigational platform.

The purpose of this page is to provide a high-level summary of the AI-assisted technical review while preserving more detailed technical analysis for appropriately controlled disclosure.

The uploaded review itself notes that the filing includes strengths such as a biologically coherent dual-mechanism rationale, two-tier Ki language for prosecution flexibility, and biosynthesis-oriented claim language, while also identifying open technical questions around synthetic disclosure, per-compound data, in vivo efficacy, PK/ADMET, dosing, and cell-line specificity.

Access to Full AI-Assisted Technical Review

The complete AI-assisted technical review for PATP1280.03 - NeuroReset™ contains additional analysis related to:

• full claim structure

• receptor affinity tiers

• selectivity interpretation

• linker chemistry strategy

• biosynthesis concepts

• technical strengths, gaps, and development considerations

Full technical review access is available to qualified parties under NDA / CDA only.

This includes:

research collaborators

university partners

strategic biotech partners

CROs

diligence-stage investors

counsel and technical reviewers

To request access, please contact BII and complete the required NDA/CDA process.